One of the actions of GLP-1 is to inhibit gastric emptying, thus slowing down its own secretion (negative feedback) upon postprandial activation
Its role is to complement lifestyle adjustments, like improved nutrition and physical activity, rather than serve as a standalone solution
While patients and health care professionals may look to unapproved versions of GLP-1 drugs, including semaglutide and tirzepatide, as an option for weight loss, this can be risky as unapproved versions do not undergo FDAs review for safety, effectiveness, and quality before they are marketed (FDA)
What are some of the signs
Symptoms often include a burning sensation in the chest, commonly referred to as heartburn, which may be accompanied by regurgitation of food or sour liquid
It therefore seems that GLP-1/exendin-4 might be acting in the VMH and LH, interacting with the AMPK/S6K signalling pathways, and modulating the activation status of AMPK and S6K in response to nutrient fluctuations